EUCTR2007-003126-15-DK进行中（未招募）1 期
Randomized trial of sequential epirubicin and docetaxel against docetaxel in patients with early operable breast cancer. - READ TOP2A
DBCG0 个研究点目标入组 1,932 人开始时间: 2008年3月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,932
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •· Radical surgery for early breast cancer according to DBCG guidelines
- •· Histological confirmation of invasive breast cancer
- •· TOP2A negative tumor
- •· Age 18 to 34 years
- •· Hormone receptor negative tumor and age 35 or older
- •· Hormone receptor positive tumor, age 35 to 59 years, and either node positive disease, tumor size > 2 cm, grade II or III or HER2 positive
- •· Verbal and written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •· Pregnancy
- •· Prior chemotherapy for any cancer
- •· Bilateral breast cancer or distant metastasis
- •· Active or uncontrolled cancer
- •· High co-morbidity score
- •· Treatment with a non-approved drug within 30 days
- •· Known hypersensitivity to any or the studie drugs
研究者
相似试验
已完成
3 期
IBCSG 15-95 - Randomised trial of high-dose epirubicin and cyclophosphamide x 3 supported by peripheral blood progenitor cells versus anthracycline and cyclophosphamide x 4 followed by cyclophosphamide, methotrexate, and 5-fluoruracil x 3 as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (<=65 yrs) patientsCancer - BreastBreast CancerACTRN12607000025437International Breast Cancer Study Group300
已完成
不适用
A randomised trial of epirubicin and cyclophosphamide versus epirubicin and paclitaxel in the treatment of women with metastatic breast cancerCancerBreast cancerISRCTN75147488Medical Research Council (MRC) (UK)700
已完成
不适用
A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinomaCancerISRCTN23062732Erasmus Medical Center, Department of Medical Oncology (Netherlands)43
招募中
不适用
Phase II randomized controlled trial of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000011785Takasaki General Medical Center, National Hospital Organization60
进行中（未招募）
1 期
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine and Herceptin in Early Breast Cancerearly HER-2 breast cancerEUCTR2004-002030-19-ATAUSTRIAN BREAST CANCER STUDY GROUP536